ID: ALA3799244

Max Phase: Preclinical

Molecular Formula: C24H29FN4O3

Molecular Weight: 440.52

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc2c(Nc3c(F)ccc(O)c3C)ncnc2cc1OCCCN1CCCCC1

Standard InChI:  InChI=1S/C24H29FN4O3/c1-16-20(30)8-7-18(25)23(16)28-24-17-13-21(31-2)22(14-19(17)26-15-27-24)32-12-6-11-29-9-4-3-5-10-29/h7-8,13-15,30H,3-6,9-12H2,1-2H3,(H,26,27,28)

Standard InChI Key:  NTMPIAZHIGNFJM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 440.52

Molecular Weight (Monoisotopic): 440.2224

AlogP: 4.79

#Rotatable Bonds: 8

Polar Surface Area: 79.74

Molecular Species: BASE

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.81

CX Basic pKa: 8.95

CX LogP: 4.04

CX LogD: 2.80

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.49

Np Likeness Score: -1.01

References

1. Jordan AM, Begum H, Fairweather E, Fritzl S, Goldberg K, Hopkins GV, Hamilton NM, Lyons AJ, March HN, Newton R, Small HF, Vishwanath S, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ..  (2016)  Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.,  26  (11): [PMID:27086121] [10.1016/j.bmcl.2016.03.100]

Source

Source(1):

• Scientific Literature